| 51 |
24485799 | Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. | 2014 Apr |
1 |
| 52 |
24899604 | Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib. | 2014 |
4 |
| 53 |
24908318 | Chromatin immunoprecipitation analysis of bortezomib-mediated inhibition of NFκB recruitment to IL-1β and TNFα gene promoters in human macrophages. | 2014 |
6 |
| 54 |
25089799 | Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma. | 2014 Nov |
1 |
| 55 |
25674239 | Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options. | 2014 |
1 |
| 56 |
22791234 | Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group. | 2013 Jul |
1 |
| 57 |
23340716 | Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells. | 2013 Mar |
5 |
| 58 |
23395385 | Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib. | 2013 Jun |
1 |
| 59 |
23416210 | Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1. | 2013 Jun |
2 |
| 60 |
23613854 | Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma. | 2013 |
1 |
| 61 |
23657944 | NF-κB inhibition by bortezomib permits IFN-γ-activated RIP1 kinase-dependent necrosis in renal cell carcinoma. | 2013 Aug |
3 |
| 62 |
23894194 | Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: the role of IKKα. | 2013 Sep 1 |
3 |
| 63 |
24055520 | Induction of steroid sulfatase expression in PC-3 human prostate cancer cells by insulin-like growth factor II. | 2013 Nov 25 |
1 |
| 64 |
24085292 | Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner. | 2013 Nov 8 |
1 |
| 65 |
24156429 | [Effect of PCI-32765 and bortezomib on proliferation and apoptosis of B-cell tumor cell lines and its mechanisms]. | 2013 Oct |
1 |
| 66 |
21792887 | Nuclear factor kappa B pathway associated biomarkers in AIDS defining malignancies. | 2012 Jun 1 |
2 |
| 67 |
22286145 | Ischemia-reperfusion injury in rat steatotic liver is dependent on NFκB P65 activation. | 2012 Jun |
1 |
| 68 |
22393418 | Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells. | 2012 |
1 |
| 69 |
22436457 | Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma. | 2012 Mar 21 |
1 |
| 70 |
22512091 | The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway. | 2012 Feb |
4 |
| 71 |
22532603 | Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs. | 2012 Jun |
1 |
| 72 |
22819259 | Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. | 2012 Oct |
2 |
| 73 |
23048077 | Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia. | 2012 Dec 15 |
2 |
| 74 |
23257433 | [Effects of arsenic trioxide combined with bortezomib on proliferation and apoptosis of K562 cells and their mechanism]. | 2012 Dec |
1 |
| 75 |
20674018 | NF-κB localization in multiple myeloma plasma cells and mesenchymal cells. | 2011 Jan |
2 |
| 76 |
21170083 | NF-κB addiction and its role in cancer: 'one size does not fit all'. | 2011 Apr 7 |
2 |
| 77 |
21174067 | Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress. | 2011 Mar |
1 |
| 78 |
21220502 | Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. | 2011 Jan |
4 |
| 79 |
21224428 | Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL. | 2011 Feb |
14 |
| 80 |
21246525 | A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303). | 2011 Aug 1 |
1 |
| 81 |
21441948 | Triptolide inhibits the proliferation of cells from lymphocytic leukemic cell lines in association with downregulation of NF-κB activity and miR-16-1*. | 2011 Apr |
1 |
| 82 |
21487323 | Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer. | 2011 Aug |
1 |
| 83 |
21768098 | Nuclear factor-kappaB (NF-kappaB) mediates a protective response in cancer cells treated with inhibitors of fatty acid synthase. | 2011 Sep 9 |
2 |
| 84 |
21850367 | Quinone methide tripterine, celastrol, induces apoptosis in human myeloma cells via NF-κB pathway. | 2011 Nov |
1 |
| 85 |
23467537 | Reversion of Multidrug-Resistance by Proteasome Inhibitor Bortezomib in K562/DNR Cell Line. | 2011 Mar |
3 |
| 86 |
19835847 | Proteasome inhibition up-regulates inflammatory gene transcription induced by an atypical pathway of NF-kappaB activation. | 2010 Mar 1 |
1 |
| 87 |
19850643 | Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. | 2010 Apr |
1 |
| 88 |
20006625 | Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. | 2010 Jan 30 |
3 |
| 89 |
20515939 | The NF-kappaB inhibitor LC-1 has single agent activity in multiple myeloma cells and synergizes with bortezomib. | 2010 Jun |
1 |
| 90 |
20592098 | The clinically approved proteasome inhibitor PS-341 efficiently blocks influenza A virus and vesicular stomatitis virus propagation by establishing an antiviral state. | 2010 Sep |
2 |
| 91 |
20649468 | The treatment of traumatic brain injury with velcade. | 2010 Sep |
1 |
| 92 |
20651984 | Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. | 2010 Jul |
1 |
| 93 |
20702412 | Pro-inflammatory genes as biomarkers and therapeutic targets in oral squamous cell carcinoma. | 2010 Oct 15 |
1 |
| 94 |
20872175 | Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. | 2010 Dec |
2 |
| 95 |
21269258 | Focal adhesion kinase as a therapeutic target of bortezomib. | 2010 Dec |
5 |
| 96 |
21472287 | Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA. | 2010 Jul-Aug |
1 |
| 97 |
18461345 | Differential radiation sensitization of human cervical cancer cell lines by the proteasome inhibitor velcade (bortezomib, PS-341). | 2009 Jan |
2 |
| 98 |
19087975 | Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors. | 2009 Apr |
1 |
| 99 |
19327235 | The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. | 2009 Jan-Feb |
2 |
| 100 |
19380866 | Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. | 2009 Jun 11 |
1 |